Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT-TN-III: Sacituzumab Govitecan +/- Pembrolizumab in Early TNBC
NCT06081244Phase 3Recruiting
- Sponsor
- Westdeutsche Studiengruppe
- Start
- Oct 2024
- Primary completion
- Sep 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sacituzumab govitecan, pembrolizumab in triple negative breast cancer (TNBC), sponsored by Westdeutsche Studiengruppe. Started Oct 2024; status: recruiting.
02
Drugs
sacituzumab govitecanpembrolizumab
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06081244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06081244.